Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism

Area of Science:

• Endocrinology and Metabolism
• Pharmacology
• Clinical Research

Background:

• Standard hypothyroidism treatment involves synthetic thyroxine (T4) replacement.
• Conflicting results exist regarding the efficacy of T4 alone versus combined T4 and triiodothyronine (T3) therapy.
• Patient well-being and quality of life are key considerations in hypothyroidism management.

Purpose of the Study:

• To systematically review randomized controlled trials comparing T4 alone with T4 plus T3 replacement therapy for hypothyroidism.
• To evaluate the effects of these therapies on psychometric function, quality of life, and cognitive performance.
• To determine the optimal therapeutic strategy for managing hypothyroidism.

Main Methods:

• Systematic review of 10 randomized, double-blind trials (6 crossover, 4 parallel).
• Searches conducted in Medline, Embase, Cochrane Library, China National Infrastructure, and manual searches of specific Chinese journals.
• Pooled analyses of biochemical variables, psychometric indices, cognitive function tests, and adverse effects.

Main Results:

• T4 plus T3 therapy increased free and total T3 but decreased serum T4 and T3 levels.
• T4 alone showed significant benefits in psychological and physical well-being, including improved general health and functioning.
• No significant differences were found in biochemical variables, mood, adverse effects, or drop-out rates between the two treatment groups.

Conclusions:

• Combined T4 and T3 treatment does not offer significant advantages over T4 alone in improving well-being, cognitive function, or quality of life.
• T4 alone replacement therapy may be sufficient and beneficial for improving psychological and physical well-being in hypothyroid patients.
• T4 alone remains the preferred drug of choice for hypothyroidism based on current evidence.